StockData

Arbutus Biopharma vs Xencor

ABUS and XNCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ABUS and XNCR compare

Xencor is the larger company, worth 3.3 times as much as Arbutus Biopharma ($2.6B against $799M).

Arbutus Biopharma grew revenue faster over the last twelve months (1079% versus −28.6% for Xencor).

Arbutus Biopharma keeps more of each dollar of sales as profit, with a net margin of 84.2% compared with −156% at Xencor.

Arbutus Biopharma scores higher on the StockData Score (14 against 5 for Xencor), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricABUSXNCR
Size and price
Market cap$799M$2.6B
Share price$4.04$35.40
Change, 1 year−11.4%153%
Change, 5 years29.1%−0.11%
Beta (5Y)1.29−0.09
Employees19260
StockData Score
Total score14 (better)5
Valuation score3 (better)0
Growth score11
Performance score4 (better)1
Health score6 (better)3
Dividend score00
Valuation
P/E5.2×–
P/S4.4× (better)25.1×
P/B3.1× (better)5.2×
EV/EBITDA4.7×–
FCF yield–−7.9%
Fair value$15.28$11.73
Margin of safety73.6% (better)−202%
Growth
Revenue growth (TTM)1079% (better)−28.6%
Revenue growth, 5Y average15.3% (better)0.47%
Profitability
Operating margin82.0% (better)−206%
Net margin84.2% (better)−156%
FCF margin–−198%
Return on equity89.6% (better)−29.1%
Return on invested capital156% (better)−26.6%
Financial health
Debt / equity0.000.21 (better)
Interest coverage1960× (better)−8.0×
Current ratio81.42 (better)6.39
Altman Z-score28.79 (better)5.19
Piotroski F-score4 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions71.1%113%
Held by insiders35.9%1.6%
Insider net buying, 12 months–−$7.5M
Short interest, % of float15.7%17.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.